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Background
In angioimmunoblastic T-cell lymphoma, symptoms linked to B-lymphocyte activation are
common, and variable numbers of CD20+ large B-blasts, often infected by Epstein-Barr virus,
are found in tumor tissues. We postulated that the disruption of putative B-T interactions
and/or depletion of the Epstein-Barr virus reservoir by an anti-CD20 monoclonal antibody (rit-
uximab) could improve the clinical outcome produced by conventional chemotherapy.
Design and Methods
Twenty-five newly diagnosed patients were treated, in a phase II study, with eight cycles of rit-
uximab + chemotherapy (R-CHOP21). Tumor infiltration, B-blasts and Epstein-Barr virus status
in tumor tissue and peripheral blood were fully characterized at diagnosis and were correlated
with clinical outcome. 
Results
A complete response rate of 44% (95% CI, 24% to 65%) was observed. With a median follow-
up of 24 months, the 2-year progression-free survival rate was 42% (95% CI, 22% to 61%) and
overall survival rate was 62% (95% CI, 40% to 78%). The presence of Epstein-Barr virus DNA
in peripheral blood mononuclear cells (14/21 patients) correlated with Epstein-Barr virus score
in lymph nodes (P<0.004) and the detection of circulating tumor cells (P=0.0019). Despite
peripheral Epstein-Barr virus clearance after treatment, the viral load at diagnosis (>100
copy/mg DNA) was associated with shorter progression-free survival (P=0.06). 
Conclusions
We report here the results of the first clinical trial targeting both the neoplastic T cells and the
microenvironment-associated CD20+ B lymphocytes in angioimmunoblastic T-cell lymphoma,
showing no clear benefit of adding rituximab to conventional chemotherapy. A strong relation-
ship, not previously described, between circulating Epstein-Barr virus and circulating tumor
cells is highlighted. (This trial was registered at www.clinicaltrials.gov as NCT00169156.)
Key words: angioimmunoblastic T-cell lymphoma, angioimmunoblastic T-cell lymphoma,
CHOP-R, Epstein-Barr virus.
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ABSTRACT
Introduction
Angioimmunoblastic T-cell lymphoma (AITL), one of the
most frequent peripheral T-cell lymphomas,1 usually affects
elderly patients in their sixth or seventh decade.2 It is clini-
cally characterized by widespread lymphadenopathy, and
commonly, extranodal disease, immune-mediated hemoly-
sis, and polyclonal hypergammaglobulinemia.3 The recent
identification of the follicular helper T cell (TFH) as the cell
of origin of this lymphoma4,5 represents a major step in the
understanding of the clinicobiological characteristics of the
disease.6 This T-cell subset promotes positive selection, pro-
liferation and differentiation of germinal center antigen-spe-
cific B cells.7 The TFH derivation of AITL provides a ration-
ale to explain the common expansion of B cells, the plasma-
cytic infiltrate in tumor biopsies, and the hypergammaglob-
ulinemia as well as the immune dysfunction manifestations
of the disease.8
The clinical course of AITL is variable, with occasional
spontaneous remissions, but overall its prognosis is poor
with affected patients having a median overall survival of
less than 3 years in most studies.6 Various treatment strate-
gies, ranging from watching and waiting to combination
chemotherapy, have proven largely insufficient. Different
combinations of chemotherapeutic drugs, such as
cyclophosphamide, doxorubicin, vincristine, and pred-
nisone (CHOP) and CHOP-like regimens, have failed to
increase the 5-year survival rate to more than 35%.9,2
Several attempts to add drugs to CHOP, such as etoposide10
and bleomycin in the MACOP-B,11 also proved unsuccess-
ful. In a large, retrospective Groupe d’Etude des Lymphomes de
l’Adulte (GELA) study of AITL patients who had been
enrolled into different therapeutic protocols,2 no positive
impact on survival was observed for any treatment, even
among patients submitted to consolidation with autologous
stem cell transplantation (ASCT). For younger and fitter
patients the indication for consolidative ASCT remains
under debate12,13 but alternative strategies need to be devel-
oped for elderly patients.
One peculiar pathological feature of AITL is the highly
variable proportion of neoplastic T cells, sometimes minor,
compared to the reactive component made up of small lym-
phocytes, histiocytes, eosinophils, plasma cells, and B
immunoblasts, suggesting a role of the microenvironment
in maintenance of tumor cell viability. Epstein-Barr virus
(EBV)-infected B-blasts are detected in most AITL.14 The
biological significance and pathophysiological implications
of this observation are still unclear. EBV infection/reactiva-
tion can occur as a consequence of an underlying “immune
dysfunction”, but no correlation between EBV and immune
parameters has been documented in AITL. EBV may,
through the modulation of cytokines, chemokines and
membrane receptors, play a paracrine role either in the
development of the tumor microenvironment,15 or in tumor
cell survival, ultimately favoring disease progression. 
Taking into account both the B-cell hyperstimulation stig-
mata associated with an increased number of B cells present
in tumor tissue of AITL and the putative feeder role of  B
cells or EBV-infected B cells for neoplastic T cells,  we pos-
tulated that AITL patients might benefit from treatment
with an anti-CD20 monoclonal antibody (rituximab) in
combination with an anthracycline-containing chemother-
apy protocol. Here we report the results of a phase II clinical
trial in which patients aged 60 to 80 years with newly diag-
nosed AITL were treated with a combination of rituximab
and CHOP (R-CHOP).  The pathological features of the
tumors and the clinically relevant immuno-biological and
viral parameters were analyzed in detail and correlated to
the clinical features.
Design and Methods
Study design
The study was a multicenter, phase II, open-label, non-random-
ized trial evaluating the efficacy of R-CHOP, delivered every 3
weeks, in patients aged 60 to 80 years with a first diagnosis of
AITL. Patients were enrolled in 11 participating centers of the
GELA.
Patients were eligible if they had not been previously treated
(except with steroids initiated less than 10 days before inclusion)
and had good performance status (ECOG PS ≤2). Additional eligi-
bility requirements included unaltered renal and hepatic function,
and adequate bone marrow reserve (neutrophils > 1.5×109/L and
platelets >100×109/L) unless alterations were related to the disease.
Non-eligibility criteria included contra-indications to any drug
included in the R-CHOP regimen, a life expectancy of less than 3
months, and central nervous system or meningeal involvement by
lymphoma. Patients with human immunodeficiency virus infec-
tion or an active hepatitis B or hepatitis C infection were also
excluded as were subjects with a previous history of cancer (except
an adequately treated non-melanoma skin cancer or in situ cervical
cancer) during the preceding 5 years. 
Initial staging included physical examination, standard laborato-
ry assessments, Coombs’ test, gammaglobulin levels, computed
tomography (CT) scans of the chest, abdomen and pelvis, and a
bone marrow biopsy. 
Patients were treated with R-CHOP (cyclophosphamide 750
mg/m2, vincristine 1.4 mg/m2 (capped at 2 mg), doxorubicin 50
mg/m2 on day 1, and prednisone 100 mg on days 1–5, each cycle
repeated every 3 weeks combined with an infusion of 375 mg/m2
rituximab) as shown in Figure 1. Patients received 15 mg of
intrathecal methotrexate on day 1 of the first four cycles. A mid-
term evaluation was performed after four cycles, and responders
(see below) received four additional cycles. Granulocyte colony-
stimulating factor (G-CSF) support was not planned. In the case of
severe neutropenia or neutropenia-related infection, subcutaneous
G-CSF was recommended from day 6 to day 13 or until the neu-
trophil count was ≥1.0x109/L, for subsequent cycles.
Study management
The GELA was the sponsor of the study. On-site monitoring
was organized in each center. All case report forms were sent to
the GELA central operation office (GELA-RC) and double data
entry was undertaken for verification purposes. Outliers and erro-
neous values were checked routinely. Queries and on-site monitor-
ing data were used for final validation, and the GELA-RC had full
control of the database. Statistical analyses were performed by the
statistical department of the GELA-RC. 
The protocol was approved by local ethic committees according
to French laws and the study was conducted in accordance with
the Declaration of Helsinki. Patients were required to provide writ-
ten informed consent prior to registration. The study is registered
with clinicaltrials.gov (NCT00169156) and had the EudraCT num-
ber 2005-002602-37.
Toxicity and response assessments
Hematologic and non-hematologic toxicities were graded
according to the National Cancer Institute Common Toxicity
Criteria (version 3.0). Toxicity was evaluated on day 1 of each
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treatment cycle and included a laboratory assessment with com-
plete blood cell count and serum chemistry tests. 
Response to induction was first evaluated at midterm, 2 weeks
after the fourth cycle. Patients who obtained a complete response,
an unconfirmed complete response or a partial response according
the International Working Group Criteria16 received four additional
cycles. Final response assessment was performed 3 to 4 weeks
after the last cycle of R-CHOP and required a bone marrow biopsy
unless the initial biopsy had been negative.
Follow-up assessments included clinical evaluation every 3
months and CT scans every 6 months for an additional 3-year
period.
Histological and immunohistochemical analyses 
and scoring
Pathological specimens were centrally reviewed in the GELA-
Pathology institute (GELA-P) and the diagnosis of AITL was con-
firmed by at least two expert hematopathologists based on the cri-
teria of the World Health Organization classification.1 Slides were
stained with hematoxylin-eosin and Giemsa and with an appropri-
ate panel of antibodies directed against B-cell antigens (CD20,
CD79a), T-cell antigens (CD3, CD2, CD5, CD7, CD4), follicular
dendritic cell antigens, CD1017 and TFH-associated molecules,
(PD1, CXCL13), as previously described.18 The diagnosis was
based on the following criteria: partial or diffuse effacement of the
nodal architecture, polymorphous cellular infiltrate, vascular prolif-
eration with prominent arborization of high endothelial venules,
extrafollicular meshwork of follicular dendritic cells, an atypical
population of CD3+ T cells, and the presence of large CD20+ B-cell
blasts with or without evidence of EBV infection. Cases were clas-
sified according to the three patterns described by Attygale.17 The
presence of EBV was investigated by in situ hybridization with
probes specific for EBV-encoded small RNA (EBER1 and 2)
sequences.2
All cases were scored by two expert pathologists (LdL, PG) for
the assessment of neoplastic T-cell content, large B-cell infiltration
as well as for the number of EBV-infected cells. The abundance of
tumor cells in proportion to overall cellularity was semi-quantita-
tively evaluated according to a score varying from 1 to 3, with
score 1 signifying <30%; score 2 signifying 30-50% and score 3 sig-
nifying >50%. The abundance of B-blasts, based on counting large
CD20+ cells in five to ten high-power microscopic fields (hpf)
(Olympus BX40), was expressed as a mean per hpf and assigned
score 1 when there were fewer than 5 B-blasts, score 2 when there
were between 5 to 50 and score 3 when there were more than 50
and/or sheets/aggregates of large CD20+ cells. The abundance of
EBV-infected cells was measured by counting the number of EBER-
positive cells in five randomly selected hpf and expressed as a score
ranging from 1 to 3 with score 1 indicating fewer than 5, score 2
indicating 5 to 15 and score 3 indicating more than 15 with or
without sheets/aggregates.
Peripheral blood and lymph node sampling
Peripheral blood samples were referred at diagnosis and at the
time of clinical response evaluation to the Immunobiology
Laboratory of Henri Mondor Hospital Center, Creteil. Lymphocyte
subpopulations were analyzed by flow cytometry on diagnostic
fresh samples (see below). Plasma samples of 1 mL were placed in
vials and stored at -80°C for further analyses. Mononuclear cells
(PBMC) were isolated from 40 mL peripheral blood by Ficoll-
hypaque density gradient centrifugation, dispatched to 10 million
cell pellet aliquots and stored at -80°C. Frozen or fixed and paraffin
embedded sections of lymph node were referred for DNA extrac-
tion. 
DNA extraction
DNA was obtained from lymph node samples using a standard
proteinase K digestion and phenol/chloroform extraction. PBMC
DNA was obtained from the frozen pellets using qiasymphony
automated extraction (Qiagen®), while DNA was extracted from
plasma samples by means of a QIAamp DNA blood minikit from
Qiagen®. 
Flow cytometry 
Absolute counts of T CD4 (CD3+ CD4+), T CD8 (CD3+ CD8+),
and B (CD19+) peripheral blood lymphocyte subsets were deter-
mined directly using Cyto-Stat tetraCHROME™ (Beckman-
Coulter). The presence of circulating tumor T cells was assessed by
at least one of the following criteria: (i) CD3–CD4+ immunopheno-
type;19 (ii) total or partial loss of pan-T antigens CD2, CD5, or
CD7, using a combination of CD2-FITC, CD7-RD1, CD3-ECD,
CD4-TRI, CD5-PC7; and (iii) co-expression of CD10.20 All antibod-
ies were from Beckman-Coulter. Flow cytometry was performed
on a Coulter FC500 within 24 h after staining. List-mode parame-
ters were analyzed and stored on CXP™ software (Beckman-
Coulter). 
Normal values were as follow:21 CD3+ T cells (536–1787
cells/mm3); helper CD4+ T cells (309–1139 cells/mm3); cytotoxic
CD8+ T cells (137–823 cells/mm3); B cells expressing CD19 (72–460
cells/mm3).
B and T lymphocyte clonality analyses
T-cell receptor gamma chain gene analysis was performed by
GC-clamp multiplex polymerase chain reaction (PCR) and dena-
m-H. Delfau-larue et al.
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Figure 1. Study design. Rituximab was administered on day 1, before doxorubicin (50 mg/m2), cyclophosphamide (750 mg/m2), and vin-
cristine (total dose 1.4 mg) and after prednisone (40 mg/m2). A midterm evaluation was performed after four R-CHOP cycles, and responders
received another four cycles.
turing gradient gel electrophoresis as previously described.22 A
dominant peripheral blood T-cell clone was considered as neoplas-
tic when the same electrophoretic imprint could be documented in
the tumor lymph node.23 For immunoglobulin heavy chain
(FR1/JH, FR2/JH, FR3/JH) and light chain (IGK, IGKDE) rearrange-
ment studies, PCR were performed according to the Biomed 2 pro-
tocol.24 Samples with an intense, unique or weak, dominant peak
on a polyclonal background were considered as clonal, those with
multiple dominant peaks were considered as oligoclonal and those
with a polyclonal pattern as non-clonal.
Epstein-Barr virus status: genome detection 
and quantification, serology
EBV DNA amplifications were performed using Mix fast DNA
LC (Roche Molecular Systems®) and analyzed in real-time on a
Light Cycler system (Roche Molecular Systems®). A sequence of
169 bp from the BXLF1 gene coding for viral thymidine kinase was
amplified using primers and probes described by Brengel-Pesce et
al.25 EBV DNA was quantified by means of an external standard
curve constructed using 10-fold dilutions of a plasmid DNA con-
taining the 169 bp fragment. Results were expressed as number of
copies per mL of plasma or per mg of PBMC DNA by means of β-
globin quantification. Specific anti-EBV antibodies (IgG anti-VCA,
IgG anti-EBNA and IgM anti-VCA) were sought in serum samples
using LIAISON® kits (Liaison® EBV VCA IgG, Liaison® EBV VCA
IgM and Liaison® EBV EBNA).
Statistical methods 
The primary endpoint was the complete response rate, includ-
ing complete response and unconfirmed complete response at the
end of treatment. Previous studies using CHOP reported an esti-
mated overall response rate of 40% in patients with AITL.26 In
order to detect an overall response rate higher than 40% after eight
cycles of R-CHOP, we calculated, using a triangular test procedure
every five patients, that a sample size of 25 assessable patients
recruited over 2 years would provide 80% power at an overall 5%
(2-sided) significance level. As one of the secondary endpoints,
progression-free survival was measured from the date of inclusion
into the study to date of progression/relapse or death from any
cause. Overall survival was calculated from the date of enrollment
until death from any cause. 
Progression-free survival and overall survival were estimated
using the product-limit method of Kaplan–Meier and compared
using the log-rank test on an intent-to-treat basis; data were cen-
sored at the date of last evaluation when the stopping date
(September 1, 2009) was not reached. Correlations between
response rate, patients’ characteristics and biological data (circulat-
ing lymphocyte phenotype, EBV status, T/B clonality) were ana-
lyzed using Fisher’s exact test. Statistical tests were considered sig-
nificant when the two-sided P value was less than 0.05.
Confidence intervals (CI) were computed with a 95% coverage;
95% CI binomial exact bounds were computed for proportions.
All statistical analyses were performed using SAS software (version
8.2; SAS Institute, Cary, NC, USA).
Results
Clinical presentation of patients
Between December 2005 and January 2008, 27 patients
were enrolled and 25 were eligible for analysis: two patients
were withdrawn before receiving any treatment, one
retracted his informed consent and another had active hep-
atitis B. The patients’ pretreatment characteristics are sum-
marized in Table 1. Their median age was 68 years (range,
60 to 79 years) and all had extensive disease including 22
(88%) with stage IV. Seventeen patients (68%) presented
with more than one extranodal site involved.
Pathological presentation 
The pathological review process confirmed histopatho-
logical and immunophenotypic features of AITL in all cases.
They corresponded to pattern III AITL with diffuse infiltra-
tion in most (n=17) cases. Results of tumor cell density scor-
ing and T-cell clonality are summarized in Figure 2A.  The
abundance of B-blasts and EBER+ cells within the tumor
was scored. Two-thirds of patients had more than five
CD20+ blasts per hpf (score 2 and 3) (Figure 2B) whereas 23
patients (92%) had EBV-infected cells. The number of
CD20+ B-blasts was not significantly correlated with either
the number of EBV-infected cells (Figure 2B) (P=0.5) or with
B-cell clonality (for details on individual patients, see Online
Supplementary Table S1).
Immunological presentation 
Hypergammaglobulinemia was found in 7/20 patients.
More precisely, two-thirds of the patients had over-repre-
sentation of at least one immunoglobulin class in serum,
mostly IgA. Immunofixation showed a monoclonal compo-
nent in two patients, and an oligoclonal pattern (multiple
peaks) in 11 patients. By including quantitative and qualita-
tive alterations, only one patient had an apparently normal
immunoglobulin repertoire (for details on individual
patients, see Online Supplementary Table S2).
Flow cytometry was performed on peripheral blood in
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Table 1. Clinical and biological characteristics of the 25 enrolled
patients at inclusion.
                                                                                 N.                      %
Clinical features                                                                                                  
Median age                                                                   66 (59-79)                   -
Sex ratio (male/female)                                                14/11                        -
Stage III/IV                                                                           25                         100
B symptoms                                                                         16                          64
International Prognostic Index higher than 2             19                          76
Bulky mass                                                                            1                            -
Six or more involved peripheral lymph node               8                           32
Bone marrow involvement                                             11/22                       50
Hepatomegaly                                                                      7                           28
Splenomegaly                                                                      12                          48
Skin involvement                                                                 5                           20
More than one extranodal site                                       17                          68
Biological data                                                                                                    
Lactate dehydrogenase higher than normal value     15                          60
Beta 2 microglobulin higher than 3 mg/L                   17/23                       74
Albumin less than 35g/L                                                 16/24                       67
Hemoglobin less than 12g/L                                             17                         68
Lymphocytosis less than 700 /mm3                               9/23                        39
Positive Coombs’ test                                                     7 / 16                      43
Hypergammaglobulinemia                                              7/20                        35
M component unique or multiple*                             15/20                       75
∗M components were identified by immunofixation.
21/25 patients. A highly variable absolute lymphocyte
count was found (Figure 3A). The most frequent quantita-
tive abnormality was T-cell lymphopenia (CD3+ <600/mm3)
in 10/21 (47%) patients. It was related to a single subset
deficiency, CD4 (n=3), or CD8+ (n=1), but more frequently
to both (n=6).  The same variability was found in the B-cell
compartment, with often profound deficiency (<20/mm3,
n=9) mostly associated with CD3+ deficiency (n=5) (for
details on individual patients, see Online Supplementary Table
S2).
Blood circulating tumor cells (3-273/mm3) were detected
by flow cytometry and/or by PCR in 12 out of 22 patients
(54%). Despite the CD4+ phenotype of lymphoma cells, the
median absolute number of CD4 cells was similar and low
in the group with [297/mm3 (63-1112)] and without [341
/mm3 (257-1395)] circulating tumor cells (Figure 3B).
Detection of circulating tumor cells was not related to bone
marrow infiltration or tumor cell density in the diagnostic
lymph node.
Epstein-Barr virus status in peripheral blood 
at diagnosis
Anti-VCA and anti-EBNA IgG were positive in 17/19 and
15/19 patients, respectively. EBV genome was found in
PBMC in 14 out of 22 studied patients (median 1.103 cp/
PBMC µg; range 6.100 to 5.104). This EBV detection correlat-
ed strongly with EBV quantification by EBER-in situ
hybridization in lymph node biopsies (all patients with EBV
in PBMC <100 copies/mg DNA had an EBER- in situ
hybridization score <1, P=0.004) (Figure 4A). 
EBV DNA normally lies inside circulating B lymphocytes,
whereas patients with active EBV replication also have
detectable viral DNA in plasma.27 We, therefore, decided to
quantify EBV genome in plasma. Out of 20 tested patients,
eight had detectable EBV DNA, including five with more
than 1000 copies/mL plasma (Online Supplementary Table S3).
Of note, one patient with negative EBV detection in lymph
node, PBMC and sera had negative anti-EBV serology.
EBV genome in PBMC or in plasma was not associated
with CD3+ lymphopenia, or with deficiency of CD4+ or
CD8+ subsets (Figure 4B). By contrast, the presence of circu-
lating EBV genome was strongly correlated with the pres-
ence of circulating tumor cells (P=0.0019) (Figure 4C). 
Treatment exposure and toxicities
Four patients stopped treatment prematurely, two
because of death from toxicity (one case of septicemia after
cycle 2 and one case of septicemia with intestinal perfora-
tion after cycle 3), one because of disease progression (after
cycle 4) and one after the physician’s decision (partial
response after cycle 4). As a result, 21 patients (84%) com-
pleted the planned eight cycles, most of them receiving
their treatment on an outpatient basis. The most common
adverse events were hematologic toxicity. Grade 3–4 neu-
tropenia and thrombocytopenia were reported in 72% and
25% of patients, respectively, during the first four cycles
and in 60% and 4% during the subsequent four cycles.
Accordingly, 21 patients required G-CSF. Only six docu-
mented infections were observed during the period of neu-
tropenia. Of note, 14 of the 22 (64%) serious adverse events
declared in nine patients were related to infections. One
additional toxic death due to a chronic inflammatory
demyelinating polyradiculoneuropathy was observed 5
months after the end of treatment, leading to a total number
of three toxic deaths.
Clinical outcome
Response at the end of treatment was assessed after treat-
ment completion for 21 patients and at premature with-
drawal for four patients. Eleven patients achieved a com-
plete or unconfirmed complete response (44%; 95% CI,
24% to 65%). Nine patients (36%) had a partial response,
two patients progressed, and three died, including one with
progressive lymphoma, leading to an overall response rate
of 80% (CI, 59% to 93%). The median response duration
was 25 months for patients achieving a complete or uncon-
firmed complete response (13.5-not reached).
With a median follow-up of 24 months (range, 2 to 38
months), the 2-year progression-free survival rate was 42%
(95% CI, 22% to 61%) (Figure 5A) and the overall survival
rate was 62% (95% CI, 40% to 78%) (Figure 5B). Six of the
nine deaths that occurred between the end of treatment and
the stopping date were attributed to lymphoma. Of note,
no patients developed diffuse large B-cell lymphoma during
the follow-up period, although some of them had
sheets/clusters of B-blasts.
Clinicobiological correlations
A relationship between rituximab-targeted cells evaluat-
ed at diagnosis and clinical outcome was determined. In
univariate analysis, B-blast density in the tumor biopsy had
no influence on clinical outcome, including response rate
(Table 2). Although the detection of EBV copies in PBMC
was not associated with response to treatment (P=0.6),
(Table 2), it tended to be associated with a shorter progres-
sion-free survival (log-rank P=0.06) (Figure 6, Table 2).
Circulating EBV was reviewed after treatment in 11
patients, five of whom were positive at diagnosis.
Conversion to seronegativity was observed in four patients
Table 2. Main pathological and biological features and correlation with out-
come.
Total CR/CRu Fisher’s Median PFS Log rank
number exact test (months)
(95% CI)
T-cell density in tumor
<30% :Score 1 3 1 7.4 (2.5-25.8)
30-50% : Score 2 13 8 16.2 (10.1-)
>50% : score 3 9 2 0.2 22.3 (7.3-28) 0.44
Circulating tumor cells
Yes 12 3 11 (6-28)
No 10 7 0.08 26 (16- NR) 0.17
B blast density in tumor
<15 (Score 1) 5 1 NA (7.4-NR)
15-50 (Score 2) 11 6 15.5 (10.1-NR)
>50 (Score 3) 9 4 0.5 22.3 (5-28) 0.7
EBV load in tissue
<5 (score 1) 16 7 22 (12-28)
≥5 (scores 2 and 3) 9 4 1 10 (6-NR) 0.2
EBV load in PBMC
<100 cp/mg 11 6 25 (15-NR)
>100 cp/mg 11 4 0.6 10 (5-28) 0.06
EBV in plasma
<100 cp/mL 13 7 26(10-28)
>100 cp/mL 7 1 0.15 10 (6-22) 0.11
NR: not reached; CR: complete response; CRu: unconfirmed complete response; PFS: progression-
free survival.
m-H. Delfau-larue et al.
1598 haematologica | 2012; 97(10)
of whom three were in complete or complete unconfirmed
response. The patient who remained positive was in partial
response.  Of note, out of the six EBV-negative patients at
diagnosis, only one converted to being positive after treat-
ment and was in partial response. 
The close relationship between circulating EBV and circu-
lating tumor cells prompted us to investigate the prognostic
value of circulating tumor cells before treatment. The detec-
tion of circulating tumor cells tended to correlate with a
poor response to treatment (75% of non-responders had
detectable circulating tumor cells (P=0.08). However, in this
limited series, it did not translate into a significantly worse
progression-free survival (log-rank P=0.17) or overall sur-
vival (log-rank P=0.8).
Discussion
In this trial, rituximab combined with the CHOP regimen
produced a high overall response rate (80%), including
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Figure 2. T-cell, B-cell and EBV scoring in tumor biopsies. All the cases were scored by two expert pathologists (LdL, PG) for the assessment
of (A) neoplastic T-cell content. Score 1 : less than 30%; score 2: 30-50%, score 3, more than 50%, (B) large B-cell infiltration. score 1, less
than 5; score 2, 5 to 50; score 3, more than 50 and/or sheets/aggregates of large CD20+ cells as well as  for the number of EBV-infected
cells.  Score 1, less than 5; score 2, 5 to 15; score 3, more than 15 with or without sheets/aggregates). T-cell clonality (A) was analyzed by
PCR on frozen or paraffin sections. All reported non-interpretable results were from fixed paraffin-embedded tissues. 
Figure 3. Peripheral blood T- and B-cell counts at presentation. Absolute counts of peripheral blood lymphocytes subsets were obtained from
total blood on a Coulter FC500 flow cytometer (Beckman-Coulter). (A) Normal CD3+, CD4+, CD8+, CD19 values21 are indicated by hatched
boxes. Median patients’ values are indicated by a horizontal line. The left scale is used for CD3, CD4, CD8 counts and the right scale for
CD19+ and tumor cells. The presence of circulating tumor T cells was assessed by at least one of the following criteria (i) CD3-CD4+
immunophenotype, (ii) total or partial loss of pan-T antigens CD2, CD5, or CD7 (iii) co-expression of CD10. (B) Median and range of the CD4+
cell count in patients with (+) or without (-) circulating tumor cells. 
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complete responses in 44% of elderly patients with AITL.
Our goal was to target CD20+ cells, including EBV-infected
B-blasts present in most AITL tumors, which might play a
feeder role for tumor cell survival in lymph nodes. The
hypothesis remains pertinent with regard to the recently
published data showing that intrafollicular maintenance of
the TFH phenotype requires the continued presence of anti-
gen-specific B cells.28,29 However, in the absence of pub-
lished data focusing specifically on AITL – and not on the
more heterogeneous group of peripheral T-cell lymphomas
– and more specifically on AITL patients over 60 treated
with chemotherapy, it remains difficult to speculate on the
potential benefit of R-CHOP in this small cohort. In the sta-
tistical design of the study, we might have overestimated
the response to CHOP we referred to in this elderly popu-
lation (40 to 45% of complete/unconfirmed complete
response). Nevertheless, the response duration observed in
this series is short and the progression-free survival is quite
disappointing and close to that previously reported with
CHOP alone.2 It is tempting to speculate that even if ritux-
imab reduces the impact of B cells on tumor cell survival,
part of the microenvironment persists after treatment and
may favor residual TFH tumor cell re-emergence.
Alternatively, residual TFH tumor cells could reconstitute a
favorable microenvironment leading to subsequent relapse.
For example, a recent report suggests that mast cells, recruit-
ed by CXCL13-secreting tumor TFH, could constitute a
major component of the AITL microenvironment.30 Finally,
treatment could select tumor cells with an acquired envi-
ronmental autonomy. In the first hypothesis, the microen-
vironment has to be targeted more broadly and
immunomodulatory drugs represent potential, good candi-
dates.31 In the last two hypotheses, more effective therapies
targeting neoplastic TFH cells are needed.  Since our study
design in 2006, numerous phase II studies have tested new
drugs targeting T cells in patients with peripheral T-cell
lymphoma, in association with CHOP or CHOP-like regi-
mens, including alemtuzumab, a monoclonal anti-CD52
antibody,32 and denileukin diftitox, an interleukin-2 protein
combined with diphtheria toxin.33 In addition to alem-
tuzumab, several novel monoclonal antibodies have shown
some early promise in peripheral T-cell lymphoma, such as
zanolimumab, a human monoclonal antibody targeting
CD4 antigen.34 More exciting are novel monoclonal anti-
bodies, currently being evaluated in autoimmune diseases,
graft tolerance or antitumor immunity, which specifically
target molecules expressed on AITL tumor cells, such as
PD135 and ICOS.36
Our biological study focusing on B cells and EBV, which
was conducted in parallel to the clinical trial in order to cor-
relate a potential benefit of rituximab with biological fea-
tures at diagnosis, provided original data regarding clinical
practice and pathophysiological hypotheses. We found cir-
culating tumor cells in 54% of patients. By comparing
results of flow cytometry and PCR clonality analyses in rou-
tine practice, we found that an abnormal circulating T-cell
clone is demonstrated more easily and more effectively by
flow cytometry than by PCR. Moreover, in the clinical set-
ting of a patient with clinically suspected AITL, complete T-
cell phenotyping, including pan-T and CD10 markers, must
be performed independently of the absolute T-cell count.
Indeed, tumor cells were detected both in patients with
(6/10) and without (3/11) lymphopenia. 
As previously reported,14 we found the EBV genome in
the great majority of tumor samples. This observation has
been proposed as a strong argument for a pathophysiologi-
cal driving role of EBV in AITL.6 In contrast, our results
demonstrate that AITL can develop in the absence of EBV.
Indeed, one patient had negative EBV serology, in addition
to the absence of EBV genome in tumor tissue and blood. In
another model, the presence of EBV is the consequence of
immune deficiency. Arguments for immunodeficiency are
the frequency of infections, which are a common cause of
death, and the occurrence of EBV-associated B-cell prolifer-
ations in AITL patients.37,38 However, immune status has not
yet been well characterized in AITL. Here we determined
the CD4+ and CD8+ T-cell counts and correlated their
m-H. Delfau-larue et al.
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Figure 4. Peripheral EBV status at diagnosis. EBV DNA was quantified
by real-time PCR on the Light Cycler system (Roche Molecular
Systems®) using an external standard plasmid curve. Results were (A)
correlated to in situ hybridization (ISH) EBV score, (B) lymphocyte sub-
set count, and (C) circulating tumor cell detection.
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absolute values to EBV status, in the tumor and in the
periphery. We found a high frequency of lymphopenia
(CD4+ or CD8+), but no correlation with EBV status, either
in the tumor or in PBMC, and, more relevant with regards
to immunodeficiency, in sera. Given the demonstration that
normal TFH cells could exert immunosuppressive effects on
CD4+ TH1 cells,39 it is possible that immune deficiency in
AITL could be related, at least in part, to the suppressive
activity of tumoral TFH. If we speculate that the detection
of circulating tumor cells reflects a high tumor load, the sup-
pressive activity of tumoral TFH  could explain the intrigu-
ing close relationship that we observed between circulating
EBV and circulating tumor cells (P=0.001). 
We have recently shown that the number of T regulatory
cells (Treg) was significantly decreased in AITL lymph
nodes compared with in follicular lymphoma and reactive
lymph nodes.40 Interestingly, two recent studies41,42 identi-
fied a new germinal center regulatory population, named
TFR, which expresses Foxp3. Experimental data from mice
suggest that TFR cells are specialized in controlling the ger-
minal center reaction by limiting the numbers of TFH cells
and inhibiting selection and outgrowth of non–antigen-
specific B cells, including those carrying self-reactive recep-
tors. The deficiency of Foxp3+ cells in AITL could explain
the frequent observation of AITL rich in large B-blasts37 as
confirmed in 36% cases of our series, independently of EBV
infection.
In conclusion, we report here the results of the first clini-
cal trial targeting both neoplastic T cells and the microenvi-
ronment-associated CD20+ B cells in AITL. Our clinical and
biological data combined with information from the litera-
ture argue against B-blasts and/or EBV having a driving role
in AITL, and point to the need for more efficient tumor cell
targeting associated with action on microenvironment
beyond the B cells.
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Figure 5. Clinical outcome. (A) Progression-free survival (PFS). (B) Overall survival (OS).
Figure 6. Progression-free survival (PFS) according to circulating EBV.
A B
References
1. Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H, et al. WHO Classification
of Tumours of Haematopoietic and
Lymphoid Tissues.  IARC Press.  Lyon: 2008. 
2. Mourad N, Mounier N, Brière J, Raffoux E,
Delmer A, Feller A, et al. Clinical, biologic,
and pathologic features in 157 patients with
angioimmunoblastic T-cell lymphoma treat-
ed within the Groupe d'Etude des
Lymphomes de l'Adulte (GELA) trials. Blood.
2008;111(9):4463-70. 
3. Lachenal F, Berger F, Ghesquières H, Biron P,
Hot A, Callet-Bauchu E, et al.
Angioimmunoblastic T-cell lymphoma.
Medicine. 2007;86(5):282-92. 
4. Dupuis J, Boye K, Martin N, Copie-Bergman
C, Plonquet A, Fabiani B, et al. Expression of
CXCL13 by neoplastic cells in angioim-
munoblastic T-cell lymphoma (AITL): a new
diagnostic marker providing evidence that
AITL derives from follicular helper T cells.
Am J Surg Pathol. 2006;30(4):490-4. 
5. de Leval L, Rickman DS, Thielen C, Reynies
AD, Huang Y, Delsol G, et al. The gene
6 12 18 24 30 36
PFS (months)
0 6 12 18 24 30 36 42
PFS (months)
No. od subjects Event Censored Median survival (95% CL)
25 64% (16) 36% (9) 16.23 (10.12   28.02)
No of subject Event Censored Median survival (95% CI)
EBV copies in PBMC <100/mg 11 45% (5) 55% (6) 25.76 (15.51   NA)
EBV copies in PBMC ≥100/mg 11 82% (9) 18% (2) 10.12 (4.99   28.02)
Log rank P=0.0608
EBV copies in PBMC <100/mg
EBV copies in PBMC ≥100/mg
No. od subjects Event Censored Median survival (95% CL)
25 48% (12) 52% (13) 28.32 (19.35   NA)
6 12 18 24 30 36
OS (months)
Su
rv
iv
al
 p
ro
ba
bi
lit
y
Su
rv
iv
al
 p
ro
ba
bi
lit
y
Su
rv
iv
al
 p
ro
ba
bi
lit
y
1
0.8
0.6
0.4
0.2
0
1
0.8
0.6
0.4
0.2
0
1
0.8
0.6
0.4
0.2
0
expression profile of nodal peripheral T-cell
lymphoma demonstrates a molecular link
between angioimmunoblastic T-cell lym-
phoma (AITL) and follicular helper T (TFH)
cells. Blood. 2007;109(11):4952-63. 
6. de Leval L, Gisselbrecht C, Gaulard P.
Advances in the understanding and manage-
ment of angioimmunoblastic T-cell lym-
phoma. Br J Haematol. 2010;148(5):673-89. 
7. Fazilleau N, Mark L, McHeyzer-Williams LJ,
McHeyzer-Williams MG. Follicular helper T
cells: lineage and location. Immunity.
2009;30(3):324-35. 
8. Vinuesa CG, Tangye SG, Moser B, Mackay
CR. Follicular B helper T cells in antibody
responses and autoimmunity. Nat Rev
Immunol. 2005;5(11):853-65. 
9. Siegert W, Agthe A, Griesser H,
Schwerdtfeger R, Brittinger G, Engelhard M,
et al. Treatment of angioimmunoblastic lym-
phadenopathy (AILD)-type T-cell lymphoma
using prednisone with or without the COP-
BLAM/IMVP-16 regimen. A multicenter
study. Kiel Lymphoma Study Group. Ann
Intern Med. 1992;117(5):364-70. 
10. Nickelsen M, Ziepert M, Zeynalova S, Glass
B, Metzner B, Leithaeuser M, et al. High-
dose CHOP plus etoposide (MegaCHOEP) in
T-cell lymphoma: a comparative analysis of
patients treated within trials of the German
High-Grade Non-Hodgkin Lymphoma
Study Group (DSHNHL). Ann Oncol.
2009;20(12):1977-84. 
11. Karakas T, Bergmann L, Stutte HJ, Jäger E,
Knuth A, Weidmann E, et al. Peripheral T-cell
lymphomas respond well to vincristine, adri-
amycin, cyclophosphamide, prednisone and
etoposide (VACPE) and have a similar out-
come as high-grade B-cell lymphomas. Leuk
Lymphoma. 1996;24(1-2):121-9. 
12. Kyriakou C, Canals C, Goldstone A,
Caballero D, Metzner B, Kobbe G, et al.
High-dose therapy and autologous stem-cell
transplantation in angioimmunoblastic lym-
phoma: complete remission at transplanta-
tion is the major determinant of Outcome-
Lymphoma Working Party of the European
Group for Blood and Marrow
Transplantation. J Clin Oncol. 2008;26(2):
218-24. 
13. Reimer P, Rüdiger T, Geissinger E, Weissinger
F, Nerl C, Schmitz N, et al. Autologous stem-
cell transplantation as first-line therapy in
peripheral T-cell lymphomas: results of a
prospective multicenter study. J Clin Oncol.
2009;27(1):106-13. 
14. Zhou Y, Attygalle AD, Chuang S, Diss T, Ye
H, Liu H, et al. Angioimmunoblastic T-cell
lymphoma: histological progression associ-
ates with EBV and HHV6B viral load. Br J
Haematol. 2007;138(1):44-53. 
15. Hsu SM, Hsu PL. Autocrine and paracrine
functions of cytokines in malignant lym-
phomas. Biomed Pharmacother. 1994;48(10):
433-44. 
16. Cheson BD, Horning SJ, Coiffier B, Shipp
MA, Fisher RI, Connors JM, et al. Report of
an international workshop to standardize
response criteria for non-Hodgkin's lym-
phomas. NCI Sponsored International
Working Group. J Clin Oncol. 1999;17(4):
1244-52. 
17. Attygalle A, Al-Jehani R, Diss TC, Munson P,
Liu H, Du M, et al. Neoplastic T cells in
angioimmunoblastic T-cell lymphoma
express CD10. Blood. 2002;99(2):627-33. 
18. Huang Y, Moreau A, Dupuis J, Streubel B,
Petit B, Le Gouill S, et al. Peripheral T-cell
lymphomas with a follicular growth pattern
are derived from follicular helper T cells
(TFH) and may show overlapping features
with angioimmunoblastic T-cell lymphomas.
Am J Surg Pathol. 2009;33(5):682-90. 
19. Serke S, van Lessen A, Hummel M, Szczepek
A, Huhn D, Stein H. Circulating CD4+ T
lymphocytes with intracellular but no sur-
face CD3 antigen in five of seven patients
consecutively diagnosed with angioim-
munoblastic T-cell lymphoma. Cytometry.
2000;42(3):180-7. 
20. Baseggio L, Berger F, Morel D, Delfau-Larue
M, Goedert G, Salles G, et al. Identification
of circulating CD10 positive T cells in
angioimmunoblastic T-cell lymphoma.
Leukemia. 2006;20(2):296-303. 
21. Bisset LR, Lung TL, Kaelin M, Ludwig E,
Dubs RW. Reference values for peripheral
blood lymphocyte phenotypes applicable to
the healthy adult population in Switzerland.
Eur J Haematol. 2004;72(3):203-12. 
22. Theodorou I, Bigorgne C, Delfau MH, Lahet
C, Cochet G, Vidaud M, et al. VJ rearrange-
ments of the TCR gamma locus in peripher-
al T-cell lymphomas: analysis by poly-
merase chain reaction and denaturing gradi-
ent gel electrophoresis. J Pathol
1996;178(3):303-10. 
23. Delfau-Larue MH, Laroche L, Wechsler J,
Lepage E, Lahet C, Asso-Bonnet M, et al.
Diagnostic value of dominant T-cell clones in
peripheral blood in 363 patients presenting
consecutively with a clinical suspicion of
cutaneous lymphoma. Blood. 2000;96(9):
2987-92. 
24. Brüggemann M, White H, Gaulard P, Garcia-
Sanz R, Gameiro P, Oeschger S, et al.
Powerful strategy for polymerase chain reac-
tion-based clonality assessment in T-cell
malignancies. Report of the BIOMED-2
Concerted Action BHM4 CT98-3936.
Leukemia. 2007;21(2):215-21. 
25. Brengel-Pesce K, Morand P, Schmuck A,
Bourgeat M, Buisson M, Barguès G, et al.
Routine use of real-time quantitative PCR for
laboratory diagnosis of Epstein-Barr virus
infections. J Med Virol. 2002;66(3):360-9. 
26. Gisselbrecht C, Gaulard P, Lepage E, Coiffier
B, Brière J, Haioun C, et al. Prognostic signif-
icance of T-cell phenotype in aggressive non-
Hodgkin's lymphomas. Groupe d'Etudes des
Lymphomes de l'Adulte (GELA). Blood.
1998;92(1):76-82. 
27. Gulley ML, Tang W. Using Epstein-Barr viral
load assays to diagnose, monitor, and pre-
vent posttransplant lymphoproliferative dis-
order. Clin Microbiol Rev. 2010;23(2):350-66. 
28. Choi YS, Kageyama R, Eto D, Escobar TC,
Johnston RJ, Monticelli L, et al. ICOS recep-
tor instructs T follicular helper cell versus
effector cell differentiation via induction of
the transcriptional repressor Bcl6. Immunity.
2011;34(6):932-46. 
29. Kerfoot SM, Yaari G, Patel JR, Johnson KL,
Gonzalez DG, Kleinstein SH, et al. Germinal
center B cell and T follicular helper cell devel-
opment initiates in the interfollicular zone.
Immunity. 2011;34(6):947-60. 
30. Tripodo C, Gri G, Piccaluga PP, Frossi B,
Guarnotta C, Piconese S, et al. Mast cells and
Th17 cells contribute to the lymphoma-asso-
ciated pro-inflammatory microenvironment
of angioimmunoblastic T-cell lymphoma.
Am J Pathol. 2010;177(2):792-802. 
31. Li S, Gill N, Lentzsch S. Recent advances of
IMiDs in cancer therapy. Curr Opin Oncol.
2010;22(6):579-85. 
32. Gallamini A, Zaja F, Patti C, Billio A, Specchia
MR, Tucci A, et al. Alemtuzumab (Campath-
1H) and CHOP chemotherapy as first-line
treatment of peripheral T-cell lymphoma:
results of a GITIL (Gruppo Italiano Terapie
Innovative nei Linfomi) prospective multi-
center trial. Blood. 2007;110(7):2316-23. 
33. Foss F, Shak-Shie N, Goy A, Jacobson E,
Avandii R, Komrokji M, et al. Phase II study
of denileukin diftitox with CHOP in PTCL.
Ann Oncol. 2008;19(suppl 4):iv113-4. 
34. d'Amore F, Radford J, Relander T, Jerkeman
M, Tilly H, Osterborg A, et al. Phase II trial of
zanolimumab (HuMax-CD4) in relapsed or
refractory non-cutaneous peripheral T cell
lymphoma. Br J Haematol. 2010;150(5):565-
73. 
35. Ascierto PA, Simeone E, Sznol M, Fu Y,
Melero I. Clinical experiences with anti-
CD137 and anti-PD1 therapeutic antibodies.
Semin Oncol. 2010;37(5):508-16. 
36. Simpson TR, Quezada SA, Allison JP.
Regulation of CD4 T cell activation and
effector function by inducible costimulator
(ICOS). Curr Opin Immunol. 2010;22(3):326-
32. 
37. Lome-Maldonado C, Canioni D, Hermine O,
Delabesse E, Damotte D, Raffoux E, et al.
Angio-immunoblastic T cell lymphoma
(AILD-TL) rich in large B cells and associated
with Epstein–Barr virus infection. A different
subtype of AILD-TL? Leukemia. 2002;16
(10): 2134-41. 
38. Tan BT, Warnke RA, Arber DA. The frequen-
cy of B- and T-cell gene rearrangements and
epstein-barr virus in T-cell lymphomas: a
comparison between angioimmunoblastic T-
cell lymphoma and peripheral T-cell lym-
phoma, unspecified with and without asso-
ciated B-cell proliferations. J Mol Diagn.
2006;8(4):466-75. 
39. Marinova E, Han S, Zheng B. Germinal cen-
ter helper T cells are dual functional regulato-
ry cells with suppressive activity to conven-
tional CD4+ T cells. J Immunol. 2007;178
(8):5010-7. 
40. Bruneau J, Canioni D, Renand A, Marafioti T,
Paterson JC, Martin-Garcia N, et al.
Regulatory T-cell depletion in angioim-
munoblastic T-cell lymphoma. Am J Pathol.
2010;177(2):570-4. 
41. Linterman MA, Pierson W, Lee SK, Kallies A,
Kawamoto S, Rayner TF, et al. Foxp3+ follic-
ular regulatory T cells control the germinal
center response. Nat Med. 2011;17(8):975-82. 
42. Amé-Thomas P, Le Priol J, Yssel H, Caron G,
Pangault C, Jean R, et al. Characterization of
intratumoral follicular helper T cells in follic-
ular lymphoma: role in the survival of malig-
nant B cells. Leukemia. 2012;26(5):1053-63.
m-H. Delfau-larue et al.
1602 haematologica | 2012; 97(10)
